4 research outputs found

    London calling?: Preferred emigration destinations among Icelandic youth

    Get PDF
    Post-print (lokagerð höfundar)Preferred emigration destinations among adolescents reflect images and stereotypes of other countries that continuously emerge in a multitude of local and global discourses and from concrete experiences with other countries. The affinities of Icelandic adolescents are split between the islands of the Northern Atlantic, continental Nordic countries, European core countries, and North American countries. If they had to leave Iceland, however, the largest proportion of Icelandic adolescents would want to move to the United States. Girls are more likely to choose the Nordic countries, in particular Denmark, while boys are more likely to choose English-speaking countries with a reputation for economic and military power such as the United States and England. Adolescents are more likely to prefer migrating to Europe rather than North America if they are proud of their Icelandic nationality, live in cohesive communities, have more educated parents, and feel closer to Europe. Adolescents who want to move abroad are in contrast most likely to have North American destinations in mind. Recent geopolitical changes may however shift the attention of Icelandic adolescents eastward towards the European continent.This article has benefited greatly from extensive discussions with Atli Hafthorsson, Brynhildur Thorarinsdottir, Kjartan Olafsson and Michael S. Gibbons, and from the pioneering scholarship of Professor Thorbjorn Broddason. The data collection was in part made possible by a grant from the University of Akureyri Research Fund.Peer Reviewe

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
    corecore